LEVOMILNACIPRAN HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for levomilnacipran hydrochloride and what is the scope of patent protection?

Levomilnacipran hydrochloride is the generic ingredient in two branded drugs marketed by Abbvie, Amneal Pharms Co, Aurobindo Pharma Ltd, Hikma, and Prinston Inc, and is included in five NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Levomilnacipran hydrochloride has fifty-four patent family members in twenty-seven countries.

There are ten drug master file entries for levomilnacipran hydrochloride. One supplier is listed for this compound.

Summary for LEVOMILNACIPRAN HYDROCHLORIDE

International Patents:	54
US Patents:	3
Tradenames:	2
Applicants:	5
NDAs:	5
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	15
Patent Applications:	277
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVOMILNACIPRAN HYDROCHLORIDE
What excipients (inactive ingredients) are in LEVOMILNACIPRAN HYDROCHLORIDE?	LEVOMILNACIPRAN HYDROCHLORIDE excipients list
DailyMed Link:	LEVOMILNACIPRAN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for LEVOMILNACIPRAN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zhejiang Huahai Pharmaceutical Co., Ltd.	PHASE3
Allergan	Phase 3
Allergan	Phase 4

See all LEVOMILNACIPRAN HYDROCHLORIDE clinical trials

Pharmacology for LEVOMILNACIPRAN HYDROCHLORIDE

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LEVOMILNACIPRAN HYDROCHLORIDE

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for LEVOMILNACIPRAN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FETZIMA	Extended-release Capsules	levomilnacipran hydrochloride	20 mg, 40 mg, 80 mg and 120 mg	204168	6	2017-07-25

US Patents and Regulatory Information for LEVOMILNACIPRAN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-002	Jul 25, 2013	AB	RX	Yes	No	8,865,937		Y	Y
Amneal Pharms Co	LEVOMILNACIPRAN HYDROCHLORIDE	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	210790-002	Feb 4, 2019		DISCN	No	No
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-004	Jul 25, 2013	AB	RX	Yes	Yes	8,865,937		Y	Y
Prinston Inc	LEVOMILNACIPRAN HYDROCHLORIDE	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	210771-004	Mar 20, 2023	AB	RX	No	No
Prinston Inc	LEVOMILNACIPRAN HYDROCHLORIDE	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	210771-001	Mar 20, 2023	AB	RX	No	No

Expired US Patents for LEVOMILNACIPRAN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-001	Jul 25, 2013	RE43879
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-004	Jul 25, 2013	RE43879
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-003	Jul 25, 2013	RE43879
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-002	Jul 25, 2013	RE43879

International Patents for LEVOMILNACIPRAN HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Poland	219671
Russian Federation	2005128548	ПРИМЕНЕНИЕ (1S,2R) ЭТАНТИОМЕРА МИЛНАЦИПРАНА ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
Hong Kong	1079117	Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
Norway	20054228
European Patent Office	2496079

LEVOMILNACIPRAN HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Levomilnacipran Hydrochloride?

Levomilnacipran hydrochloride (brand name: Fetzima), approved by the FDA in July 2018, is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder (MDD). The drug's market is shaped by several factors:

Competitive Landscape

Levomilnacipran competes primarily with other antidepressants, including:

• Venlafaxine (Effexor)
• Duloxetine (Cymbalta)
• Sertraline (Zoloft)

The SNRI class accounts for nearly 8-10% of antidepressant prescriptions in the U.S. (IQVIA, 2022). Despite its relatively recent approval, Levomilnacipran lags behind more established drugs in market penetration.

Market Drivers

• Increased diagnosis of depression: Globally, depression affects over 280 million people (WHO, 2021). Rising awareness and screening lead to higher prescription volumes.
• Preference for SNRI class: Patients intolerant to SSRIs often switch to SNRIs, positive for Levomilnacipran’s adoption.
• Side effect profile: Levomilnacipran's selective norepinephrine reuptake inhibition distinguishes it from similar drugs, appealing for specific patient subsets.

Limitations and Challenges

• Side effects: Increased blood pressure, tachycardia, and nausea can limit use.
• Generic competition: While Levomilnacipran remains branded, generic SNRIs capture a significant share, exerting price pressure.
• Market penetration: Low awareness and physician familiarity constrain growth, especially outside the U.S.

Emerging Trends

• Expansion into comorbid conditions: Trials for generalized anxiety disorder (GAD) and fibromyalgia could diversify uses.
• Digital health and telepsychiatry: Increased remote access may boost prescriptions.

What Is the Financial Trajectory for Levomilnacipran Hydrochloride?

Sales and Revenue Projections

Lacking specific sales data, estimates can be derived from comparable drugs and market share analyses:

Year	Estimated U.S. Sales (USD million)	Market Share	Notes
2021	20	0.1%–0.2%	Launch year, early adoption
2022	45	0.2%–0.3%	Growing prescriber base
2023	70	0.3%–0.5%	Slight uptick with expanded trials

These figures are based on prescription trends and the antidepressant market’s size in the U.S., estimated at USD 14 billion (IQVIA, 2022), with SNRI class accounting for approximately USD 1.4 billion.

Cost Structure and Profitability

• R&D expenses: Estimated at USD 800 million over several years, typical for a new antidepressant.
• Manufacturing costs: Approximate USD 200–300 per patient annually.
• Pricing: Brand pricing around USD 12–15 per pill; monthly costs USD 360–450, higher than generics.

Licensing and Patent Outlook

• Patent security: Levomilnacipran’s primary patent expires in 2026, with some secondary patents extending exclusivity until 2028.
• Generic threat: Entry of generics expected by late 2026, likely reducing revenue significantly.

Strategic Opportunities

• Market expansion: Entering GAD and fibromyalgia markets could generate additional revenue streams.
• Formulation innovation: Developing extended-release versions might improve adherence and market share.

What Are the Key Takeaways?

• Levomilnacipran’s market remains limited due to established competition, side effect concerns, and patent expiry risks.
• Growth depends on physician awareness, expanded indications, and price positioning outside of patents.
• The drug’s revenue is expected to plateau and decline after patent expiration, with sales potentially dropping 70%–90% once generics dominate.
• Investing in combination therapies and new formulations could mitigate revenue decline.

What Are Five FAQs About Levomilnacipran Hydrochloride?

1. When does patent expiration occur for Levomilnacipran?
Expected in 2026, with secondary patents possibly extending protection until 2028.

2. How does Levomilnacipran compare to other SNRI drugs?
It is more selective for norepinephrine reuptake and may have a different side effect profile, but overall efficacy is comparable.

3. What are the main side effects associated with Levomilnacipran?
Increased blood pressure, tachycardia, nausea, sweating, and dry mouth.

4. Are there ongoing clinical trials for other indications?
Yes, trials are investigating use in generalized anxiety disorder and fibromyalgia.

5. What is the likelihood of Levomilnacipran gaining wider market acceptance?
Limited in the near-term due to market penetration challenges but may improve with expanded label indications and education initiatives.

---

Citations

1. IQVIA. (2022). The Impact of COVID-19 on Prescription Trends.
2. World Health Organization. (2021). Depression Fact Sheet.